OM
BEARISH
$4.35
Live
Outset Medical, Inc. · NASDAQ
Target $9.0
(+106.9%)
$3.0
52W Range
$21.98
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 16, 2026
Market cap
$79.66M
P/E
N/A
ROE
-106.2%
Profit margin
-68.3%
Debt/Equity
0.8
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
90%
Outset Medical exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. Despite a strong current ratio of 6.67 suggesting short-term liquidity, the company suffers from catastrophic long-term price erosion (-99.5% over 5 years) and negative revenue growth. The combination of deep negative profit margins (-68.34%) and consistent insider selling suggests a lack of confidence in a turnaround. While analysts maintain a 'buy' rating with a $9.00 target, the deterministic data points to a high risk of further capital impairment.
Key Strengths
Strong short-term liquidity with a Current Ratio of 6.67
Low Price-to-Book ratio (0.62) suggesting the stock trades below liquidation value
Low Price-to-Sales ratio (0.67) relative to healthcare sector averages
High Quick Ratio (5.24) indicating minimal reliance on inventory for liquidity
Positive analyst target price ($9.00) providing potential upside if a catalyst emerges
Key Risks
Severe fundamental weakness indicated by a Piotroski F-Score of 1/9
Negative revenue growth (-2.00% YoY) indicating a lack of market traction
Extreme profitability deficit with a Profit Margin of -68.34%
Catastrophic historical price performance (-99.5% 5-year change)
Bearish insider sentiment with 13 sell transactions and zero buys
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
15
Weak
40
20
5
10
0
AI Verdict
High-Risk Speculative/Distressed
Key drivers: Piotroski F-Score of 1/9, Negative Revenue Growth, Catastrophic 5Y Price Action, Insider Selling
Confidence
95%
Value
40/100
Trades at a deep discount to book value, but value is irrelevant without a path to profitability.
Positives
- P/B of 0.62
- P/S of 0.67
Watchpoints
- No Graham Number due to negative earnings
- Negative Forward P/E
Future
20/100
Growth metrics are stagnant or declining, contradicting the 'growth' narrative.
Positives
- Analyst target price suggests 100%+ upside
Watchpoints
- Negative YoY Revenue Growth
- Negative Q/Q Revenue Growth
Past
5/100
Total collapse of shareholder value over a 5-year horizon.
Positives
No standout positives identified.
Watchpoints
- 5Y Change: -99.5%
- 1Y Change: -61.8%
Health
10/100
Liquidity is currently sufficient, but operational health is critical.
Positives
- High Current Ratio
Watchpoints
- Piotroski F-Score 1/9
- ROE of -106.20%
Dividend
0/100
Non-dividend paying growth/distressed company.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 strength score
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$4.35
Analyst Target
$9.0
Upside/Downside
+106.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for OM and closest competitors.
Updated 2026-04-15
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
OM
Outset Medical, Inc.
Primary
|
-99.5% | -98.4% | -61.8% | -67.9% | +29.9% | +3.6% |
|
AMWL
American Well Corporation
Peer
|
-99.3% | -93.4% | -55.6% | -45.6% | +6.1% | +3.4% |
|
PARK
Park Dental Partners, Inc.
Peer
|
+75.8% | +75.8% | +75.8% | +75.8% | +5.4% | +1.2% |
|
QTI
QT Imaging Holdings, Inc.
Peer
|
-95.3% | -95.6% | -34.0% | -78.7% | +0.9% | +0.3% |
|
ASRT
Assertio Holdings, Inc.
Peer
|
-80.4% | -85.9% | -2.8% | -7.5% | -1.3% | -1.5% |
OM
Outset Medical, Inc.
Primary
5Y
-99.5%
3Y
-98.4%
1Y
-61.8%
6M
-67.9%
1M
+29.9%
1W
+3.6%
AMW
American Well Corporation
Peer
5Y
-99.3%
3Y
-93.4%
1Y
-55.6%
6M
-45.6%
1M
+6.1%
1W
+3.4%
PAR
Park Dental Partners, Inc.
Peer
5Y
+75.8%
3Y
+75.8%
1Y
+75.8%
6M
+75.8%
1M
+5.4%
1W
+1.2%
QTI
QT Imaging Holdings, Inc.
Peer
5Y
-95.3%
3Y
-95.6%
1Y
-34.0%
6M
-78.7%
1M
+0.9%
1W
+0.3%
ASR
Assertio Holdings, Inc.
Peer
5Y
-80.4%
3Y
-85.9%
1Y
-2.8%
6M
-7.5%
1M
-1.3%
1W
-1.5%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-1.83
PEG Ratio
N/A
P/B Ratio
0.62
P/S Ratio
0.67
EV/Revenue
0.1
EV/EBITDA
-0.19
Market Cap
$79.66M
Profitability
Profit margins and return metrics
Profit Margin
-68.34%
Operating Margin
-61.06%
Gross Margin
39.13%
ROE
-106.2%
ROA
-15.43%
Growth
Revenue and earnings growth rates
Revenue Growth
-2.0%
Earnings Growth
N/A
Q/Q Revenue Growth
-2.01%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.8
Moderate
Current Ratio
6.67
Strong
Quick Ratio
5.24
Excellent
Cash/Share
$9.23
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
42.4%
Op. Margin
-61.1%
Net Margin
-67.5%
Total Assets
$0.3B
Liabilities
$0.1B
Equity
$0.1B
Debt/Equity
1.08x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
102%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-11
$-0.84
-24.4% surprise
2025-11-10
$-0.69
-5.3% surprise
2025-08-06
$-0.84
+14.5% surprise
Healthcare Sector Comparison
Comparing OM against 421 companies in the Healthcare sector
(25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
-106.2%
This Stock
vs
-100.15%
Sector Avg
+6.0%
(Above Avg)
Profit Margin
-68.34%
This Stock
vs
-13.63%
Sector Avg
+401.5%
(Superior)
Debt to Equity
0.8
This Stock
vs
3.22
Sector Avg
-75.2%
(Less Debt)
Revenue Growth
-2.0%
This Stock
vs
121.05%
Sector Avg
-101.7%
(Slower)
Current Ratio
6.67
This Stock
vs
4.55
Sector Avg
+46.5%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
OM
Outset Medical, Inc.
|
BEARISH | $79.66M | - | -106.2% | -68.3% | $4.35 | |
|
AMWL
American Well Corporation
|
BEARISH | $79.73M | - | -37.0% | -42.8% | $4.87 | Compare |
|
PARK
Park Dental Partners, Inc.
|
NEUTRAL | $81.36M | - | -4.1% | -0.1% | $18.02 | Compare |
|
QTI
QT Imaging Holdings, Inc.
|
BEARISH | $83.45M | - | -% | -111.4% | $6.93 | Compare |
|
ASRT
Assertio Holdings, Inc.
|
BEARISH | $74.82M | - | -24.5% | -21.1% | $11.66 | Compare |
OM
Outset Medical, Inc.
BEARISH
Mkt Cap
$80M
P/E
-
ROE
-106.2%
Price
$4.35
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-06 | ELLIOTT DERICK A | Officer | Stock Award | 96,000 | - |
| 2026-02-17 | BROTTEM JOHN L. | General Counsel | Sale | 2,842 | $9,521 |
| 2026-02-17 | NASH MARC | Officer | Sale | 1,817 | $6,087 |
| 2026-02-17 | TRIGG LESLIE L | Chief Executive Officer | Sale | 3,361 | $11,259 |
| 2026-01-21 | BROTTEM JOHN L. | General Counsel | Sale | 10,494 | $53,599 |
| 2026-01-21 | NASH MARC | Officer | Sale | 6,355 | $32,400 |
| 2026-01-21 | TRIGG LESLIE L | Chief Executive Officer | Sale | 13,914 | $71,091 |
| 2026-01-09 | PRANGE KAREN N. | Director | Stock Award | 18,667 | - |
| 2026-01-07 | BROTTEM JOHN L. | General Counsel | Sale | 224 | $956 |
| 2026-01-07 | NASH MARC | Officer | Sale | 108 | $461 |
| 2026-01-07 | TRIGG LESLIE L | Chief Executive Officer | Sale | 1,795 | $7,665 |
| 2025-12-01 | DREXLER KAREN | Director | Sale | 1,548 | $6,765 |
| 2025-11-17 | BROTTEM JOHN L. | General Counsel | Sale | 388 | $1,785 |
| 2025-11-17 | NASH MARC | Officer | Sale | 247 | $1,136 |
| 2025-11-17 | TRIGG LESLIE L | Chief Executive Officer | Sale | 916 | $4,214 |
ELLIOTT DERICK A
Officer
2026-04-06
96,000 shares
BROTTEM JOHN L.
General Counsel
2026-02-17
2,842 shares
·
$9,521
NASH MARC
Officer
2026-02-17
1,817 shares
·
$6,087
TRIGG LESLIE L
Chief Executive Officer
2026-02-17
3,361 shares
·
$11,259
BROTTEM JOHN L.
General Counsel
2026-01-21
10,494 shares
·
$53,599
NASH MARC
Officer
2026-01-21
6,355 shares
·
$32,400
TRIGG LESLIE L
Chief Executive Officer
2026-01-21
13,914 shares
·
$71,091
PRANGE KAREN N.
Director
2026-01-09
18,667 shares
BROTTEM JOHN L.
General Counsel
2026-01-07
224 shares
·
$956
NASH MARC
Officer
2026-01-07
108 shares
·
$461
TRIGG LESLIE L
Chief Executive Officer
2026-01-07
1,795 shares
·
$7,665
DREXLER KAREN
Director
2025-12-01
1,548 shares
·
$6,765
BROTTEM JOHN L.
General Counsel
2025-11-17
388 shares
·
$1,785
NASH MARC
Officer
2025-11-17
247 shares
·
$1,136
TRIGG LESLIE L
Chief Executive Officer
2025-11-17
916 shares
·
$4,214
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
3 analysts
BTIG
2026-02-12
Buy
Buy
Stifel
2026-01-07
Buy
Buy
BTIG
2025-12-16
Buy
Buy
Stifel
2025-11-11
Buy
Buy
RBC Capital
2025-11-11
Sector Perform
Sector Perform
BTIG
2025-11-11
Buy
Buy
Past News Coverage
Recent headlines mentioning OM from our newsroom.
Newest → oldest
No matching news yet.